Network and Slowdown

Network and Slowdown

Doximity runs the largest professional network of U.S. physicians and sells access to it, mainly to drug makers and hospitals. It is genuinely profitable and cash-rich: FY2026 revenue of $645 million at an 89% gross margin, $317 million of free cash flow, and $749 million of cash and securities against no debt [1] [2]. Yet the shares, near $22, have fallen about 70% from September 2025 as revenue growth halved to 13% and management guided the next year to 4%.

Doximity's growth reset from 20% to a guided 4% reached its biggest, most committed customers — top-20 net revenue retention fell from 119% to 114% and the over-$500k cohort's growth halved to 6% — so the deceleration is not only in the marginal spend a cyclical rebound would restore. [3] [4] If that slide in the anchor accounts is structural rather than a matter of timing, the guided ~4% for FY2027 — about $670 million at the midpoint, down from roughly 20% two years earlier — is closer to a new base rate than a trough: the discounted-cash-flow work in What the Price Implies puts the ceiling case near $19 a share on reported free cash flow and about $14 on owner cash, at or below today's $21.77, so a durable top-20 decline validates the ceiling column rather than a recovery. The strongest facts on the other side sit in the same window: net revenue retention is still above 100%, so the installed base kept growing; the pricing shock that hit the fourth quarter landed on the same 16 of the top-20 pharmaceutical accounts and disrupted the timing of budgets rather than the demand behind them [5]; and January pharmaceutical bookings were the best Doximity has reported since its 2021 IPO [6].

What Doximity is

Doximity is a cloud platform for U.S. medical professionals. As of March 2026 it had more than 3 million registered members, representing over 85% of U.S. physicians across every specialty, roughly 90% of graduating medical students, and two-thirds of nurse practitioners and physician assistants [7]. Doctors use it free — to message colleagues, read medical news, manage their careers and on-call schedules, run telehealth visits, and, increasingly, to run AI search and clinical documentation tools.

The money comes from the other side of the network. Doximity's paying customers are primarily pharmaceutical manufacturers and health systems, who buy Marketing, Hiring, and Workflow solutions to reach that verified physician audience [8]. About 94% of FY2026 revenue was subscription-based, and marketing to physicians — pharma advertising — is by far the largest line [9]. It is, in effect, a targeted-advertising and hiring marketplace wrapped around a professional network — with the unusual property that the audience is nearly the entire profession.

Sources: FY2026 Form 10-K, Item 1 and Liquidity [10] [11]; free cash flow per the Q4 FY2026 earnings call [12].

The economics are unusually clean

Doximity does not look like a typical recently-listed software company. Gross margin has held near 89–90% for years, and the business has been GAAP-profitable throughout its public life [13]. Revenue has grown from $344 million in FY2022 to $645 million in FY2026, while operating cash flow rose from $127 million to $326 million over the same span — the company converts roughly half of revenue to cash [14] [15].

Sources: FY2026 Form 10-K, Consolidated Statements of Operations and Cash Flows [16]; FY2024 Form 10-K for FY2022–FY2023 [17].

That cash has funded aggressive buybacks rather than acquisitions or debt paydown. Doximity completed a $500 million repurchase program and, in FY2026 alone, bought back $432 million of stock — more than its free cash flow — spending steadily as the price fell, including 2.7 million shares in March 2026 at an average of $24.45 [18]. A fresh $500 million authorization was set in February 2026 [19]. The net effect: shares outstanding have fallen even as the company issues heavy stock compensation.

What changed

Three things turned at once in FY2026, and together they reset how the market values the business.

Growth halved. Revenue rose 13% in FY2026, down from 20% in FY2025, and management guided FY2027 revenue of $664–676 million — about 4% growth — citing a soft market for physician-directed pharma advertising and customers signing shorter, smaller commitments [20] [21]. Net revenue retention — subscription revenue from existing customers versus the prior year — fell to 109% from 119% [22].

The bottom line dipped. Net income fell to $196 million from $223 million, even as revenue grew, because stock-based compensation jumped to $122 million from $72 million — pushing operating margin down to 33% from 40% [23]. Management guides stock comp higher still in FY2027, to the low-20s as a percent of revenue [24]. This is the gap between GAAP earnings and cash flow that any buyer of the stock has to weigh.

Concentration rose. For the first time, a single customer accounted for 10% or more of total revenue in FY2026 — a threshold no customer had crossed in FY2025 or FY2024 — and the 125 customers spending at least $500,000 each supply 83% of revenue [25] [26].

Sources: FY2026 Form 10-K, Results of Operations and Key Business Metrics [27] [28].

The bet management is making

Doximity calls FY2027 its "AI investment year." It bought Pathway AI for $63 million in 2025 and is spending heavily against the opportunity: research and development rose to $131 million from $93 million, and the company says higher R&D, compute, and marketing costs will weigh on near-term margins [29] [30]. The product is a clinical AI suite — search and documentation ("Scribe") tools for doctors — which 140 health systems had purchased as of the call, and which management frames as a "multibillion-dollar new TAM" of AI-search advertising layered on top of the roughly $2.5–3 billion digital physician-advertising market it serves today [31] [32].

By management's own guidance, AI contributes minimal revenue in FY2027 [33]. So the near-term picture is a mature core growing slowly while the company funds an option on a larger market — with the cost visible now and the payoff, if any, later.

What the stock has done

Doximity priced its IPO at $26.00 in June 2021, traded above $100 within months, then round-tripped [34]. More relevant is the recent move: the shares had recovered to roughly $73 by September 2025, near their post-IPO highs, before falling to about $22 by mid-2026 — a decline of around 70% in nine months, and near an all-time low — driven by the growth reset described above rather than by the 2021 bubble.

Source: market prices, as reported (quarter-end closes, June 2021 – July 2026); IPO price per the Final Prospectus [35].

At about $22, and roughly 183 million shares outstanding, the market capitalization is near $4.0 billion [36]. Backing out the $749 million of cash and securities leaves an enterprise value near $3.2 billion — roughly 10 times FY2026 free cash flow [37] [38]. That is an inexpensive multiple for a business with 89% gross margins and no debt, which makes the case most sensitive to which reading of the slowdown holds.

The question this report will answer

Doximity is not a broken business; it is a highly profitable one whose growth engine has downshifted from 20% to a guided 4% in two years, while net revenue retention slipped below 110% and customer concentration rose. The question the rest of this report exists to answer: is that deceleration the arrival of a ceiling — a network that has already signed most of the pharmaceutical and health-system budgets it can reach — or a cyclical soft patch in physician-directed advertising that Doximity's near-universal reach and its self-funded pivot to clinical-AI monetization can eventually grow past? Everything that follows — the durability of the moat, the true cash economics net of stock compensation, the pharma-ad cycle, the AI opportunity, and the roughly $3.2 billion enterprise value at about ten times free cash flow — informs that judgment.